Juvenile Myoclonic Epilepsy: Seizure and Social Outcomes in Taiwan

Siew-Na Lim1,2, Tony Wu1,2, Wei-En Johnny Tseng1,2,3

  • 1Section of Epilepsy, Department of Neurology, Chang Gung Memorial Hospital at Linkou Medical Center, Taoyuan 333, Taiwan.

Insights

Juvenile myoclonic epilepsy (JME) patients often have ongoing seizures despite medication. Poor seizure control is linked to lower employment, highlighting significant socioeconomic impacts.

Area of Science:

  • Neurology
  • Clinical Medicine
  • Epilepsy Research

Background:

  • Juvenile myoclonic epilepsy (JME) is a common epilepsy syndrome.
  • Many patients do not achieve complete seizure freedom with antiseizure medications (ASMs).
  • Understanding factors influencing JME outcomes is crucial for patient management.

Purpose of the Study:

  • To investigate clinical and social features of JME patients.
  • To identify factors associated with seizure control and treatment outcomes.
  • To explore the relationship between seizure status and employment.

Main Methods:

  • Retrospective study of 49 JME patients at a Taiwanese epilepsy center.
  • Patients categorized into seizure-free (≥1 year) and ongoing seizure groups.
  • Comparison of clinical features, EEG findings, and social status between groups.

Main Results:

  • 49% of JME patients achieved seizure freedom for at least one year.
  • Ongoing seizures occurred in 51% despite multiple ASMs.
  • Epileptiform discharges on EEG and nocturnal seizures correlated with worse outcomes.
  • Seizure-free patients had significantly higher employment rates (75% vs. 32%).

Conclusions:

  • A substantial proportion of JME patients experience persistent seizures despite ASMs.
  • Poor seizure control negatively impacts employment and socioeconomic status.
  • Further research is needed to improve JME management and patient quality of life.

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
234
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
479
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
93
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
227
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
481
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
444